Navigation Links
Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
Date:12/9/2010

BRIDGEWATER, N.J., Dec. 9, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the final survival analysis (10-year follow-up) of the BCIRG001 study that included a Taxotere® (docetaxel) Injection Concentrate chemotherapy treatment regimen in the adjuvant breast cancer setting, as well as data from iniparib (BSI-201) pre-clinical and clinical breast cancer studies will be featured during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas from December 8 to 12, 2010.  

During SABCS, the final (10-year follow up) survival analysis of the BCIRG001 study that included sanofi-aventis' chemotherapy drug Taxotere, in combination with doxorubicin and cyclophosphamide, in women with operable node-positive breast cancer will be presented. Also being presented are data from pre-clinical and clinical studies involving the sanofi-aventis investigational compound iniparib (BSI-201), which is being studied in breast cancer.  Iniparib is a novel investigational small molecule with poly (ADP-ribose) polymerase (PARP) inhibitory activity.

Key events at SABCS include: Taxotere Data:Abstract #S4-3

Friday, Dec. 10

3:45 PM CSTAn oral presentation featuring final results from the ten-year follow-up analysis of the BCIRG 001 trial Iniparib Data:Abstract #P5-06-09

Phase 1b/2 MBC trial

Saturday, Dec. 11

5:30 - 7:30 PM CSTData from a Phase 1b study to assess the safety and tolerability of the investigational compound iniparib (BSI-201) in combination with irinotecan in patients with metastatic breast cancer (MBC)Iniparib Data:Abstract # P6-04-12

Activity in TNBC Cell lines

Sunday, Dec. 12

7:00 - 8:30 AM CSTData from a preclinical study assessing the cell cycle effects of the investigational compound iniparib (BSI-201) in combination
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
2. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
3. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
4. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
5. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
6. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
7. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
8. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
9. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , LAS ANGELES, ... that it would initiate a programme of,regular updates to shareholders, ... in the fulfilment of its business plan, as,well as to ... Dunn Capital Partners and others. , ...
... , CENTENNIAL, Colo., Dec. 2 AlloSource, one of the ... allografts for use in surgical procedures and the world,s largest ... sponsorship of a truly iconic symbol of hope as a ... January 1, 2010 Tournament of Roses Parade®. Manuel Salazar, ...
Cached Medicine Technology:Fountain Healthy Aging Inc Business Update For Shareholders 2Fountain Healthy Aging Inc Business Update For Shareholders 3AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... the open access journal BMC Medicine has found that the ... in India are flawed and the actual number of cases ... are from the Administrative Staff College of India, conducted the ... Medical Sciences in Hyderabad. ,According to the ...
... of his family served in the Indian Army and battled the ... Sena Medal winner// and with ‘Showrya’ meaning ‘brave’ for a name, ... family path. ,But a fall from the first floor ... the one-and-a-half-year-old Showrya Malik, who was pronounced ‘brain dead’ the next ...
... Pradesh government is considering setting up a medical and health ... Health Minister Ajay Vishnoi said Tuesday. ,"The government ... Medical Council of India for opening the university," Vishnoi told ... workshop on Indian medical systems. ,"The need ...
... are not protected from attacks or stroke by taking a ... ,Folic acid or folate is one of the B Vitamins ... medical practitioners prescribe it to prevent cardiac problems. ... Health and Tropical Medicine, New Orleans led a research on ...
... damaging to health, but obesity has higher damaging properties, ... cancers reducing a person’s life span by seven years ... ,Ken Snider, advisor at NICE i.e. National Institute for ... not only to do with weight loss but also ...
Cached Medicine News:Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:A ‘Brave’ Toddler-The Youngest Organ Don 2Health News:Ways to Fight Childhood Obesity 2
... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
Medicine Products: